Ascendis Pharma A/S
NASDAQ:ASND

Watchlist Manager
Ascendis Pharma A/S Logo
Ascendis Pharma A/S
NASDAQ:ASND
Watchlist
Price: 137.975 USD 1.17%
Market Cap: 8.2B USD
Have any thoughts about
Ascendis Pharma A/S?
Write Note

Ascendis Pharma A/S
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ascendis Pharma A/S
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Ascendis Pharma A/S
NASDAQ:ASND
Cash from Financing Activities
€437.8m
CAGR 3-Years
5%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Cash from Financing Activities
-kr3.6B
CAGR 3-Years
-108%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Cash from Financing Activities
kr8.3B
CAGR 3-Years
132%
CAGR 5-Years
66%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Cash from Financing Activities
-kr35.6m
CAGR 3-Years
N/A
CAGR 5-Years
35%
CAGR 10-Years
-22%
Bioporto A/S
CSE:BIOPOR
Cash from Financing Activities
kr74.8m
CAGR 3-Years
-7%
CAGR 5-Years
0%
CAGR 10-Years
6%
Saniona AB
STO:SANION
Cash from Financing Activities
kr51.3m
CAGR 3-Years
-54%
CAGR 5-Years
5%
CAGR 10-Years
N/A
No Stocks Found

Ascendis Pharma A/S
Glance View

Market Cap
8.4B USD
Industry
Biotechnology

Ascendis Pharma A/S has established itself as a dynamic force within the biotechnology sphere, driven by a patented technology platform designed to address unmet medical needs. Founded in 2006 and headquartered in Denmark, the company has honed its focus on developing therapies to improve patients' lives by addressing significant health conditions, primarily in the fields of endocrinology and oncology. At the heart of its strategy is the TransCon technology, which revolves around prodrug methodologies that release active drug molecules at controlled rates, enhancing efficacy and reducing side effects. This platform allows Ascendis to develop extended-release versions of existing drugs, ensuring a more sustained therapeutic effect. Financially, Ascendis generates revenue by forging strategic partnerships and licensing agreements, enabling it to share in the commercialization success of its innovative pipeline products. By collaborating with larger pharmaceutical firms, Ascendis scales its impact, leveraging shared resources and expertise to bring its specialized treatments to market. Moreover, as its pipeline matures, it seeks to capitalize on successful clinical trials by moving products into commercial phases, which can result in additional income streams from direct product sales. The journey of Ascendis Pharma is emblematic of its commitment to innovation, sustainability, and delivering tangible healthcare advances through its robust technology-driven approach.

ASND Intrinsic Value
168.552 USD
Undervaluation 18%
Intrinsic Value
Price

See Also

What is Ascendis Pharma A/S's Cash from Financing Activities?
Cash from Financing Activities
437.8m EUR

Based on the financial report for Sep 30, 2024, Ascendis Pharma A/S's Cash from Financing Activities amounts to 437.8m EUR.

What is Ascendis Pharma A/S's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-2%

Over the last year, the Cash from Financing Activities growth was 209%. The average annual Cash from Financing Activities growth rates for Ascendis Pharma A/S have been 5% over the past three years , -2% over the past five years .

Back to Top